Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phosphorylation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Phosphorylation. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2008-006931-11 Sponsor Protocol Number: CPKC412A2114 Start Date*: 2009-11-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynami...
    Medical condition: in pediatric patients with relapsed or refractory leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000835 Acute leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006695-38 Sponsor Protocol Number: 06 037 03 Start Date*: 2007-02-02
    Sponsor Name:CHU Toulouse
    Full Title: Evaluation pharmacologique des antagonistes du récepteur P2Y12 à l'ADP chez le volontaire sain
    Medical condition: Volontaires sains
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001288-26 Sponsor Protocol Number: DASAHIVCURE Start Date*: 2022-08-18
    Sponsor Name:IDIBAPS
    Full Title: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection
    Medical condition: Recent HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10058427 Primary HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023508-28 Sponsor Protocol Number: CAMN107GB05T Start Date*: 2011-04-14
    Sponsor Name:Plymouth Hospital NHS Trust
    Full Title: A CLINICAL TRIAL OF THE INTRA-TUMOURAL CONCENTRATION AND ACTIVITY OF NILOTINIB IN INTRA-CUTANEOUS SCHWANNOMAS
    Medical condition: In vivo investigation of the intra-tumoural concentration and activity of nilotinib in cutaneous schwannomas (CS) in patienst with Neurofibromatosis 2
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000578-37 Sponsor Protocol Number: NL50679.068.15 Start Date*: 2015-05-20
    Sponsor Name:Maastricht University Medical Centre+
    Full Title: The effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss During Immobilisation
    Medical condition: Muscle disuse atrophy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012714-49 Sponsor Protocol Number: CHUBX 2009/04 Start Date*: 2009-11-24
    Sponsor Name:CHU de Bordeaux
    Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy
    Medical condition: Bladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005015 Bladder carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019154-40 Sponsor Protocol Number: DOSAPI Start Date*: 2010-05-19
    Sponsor Name:Medco Health Solutions, Inc.
    Full Title: Doubler la dose du clopidogrel ou passer au Prasugrel pour contrer l’interaction liée aux inhibiteurs de pompe à protons
    Medical condition: Maladie des artères coronaires
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011099 Coronary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000418-20 Sponsor Protocol Number: D1450C00001 Start Date*: 2006-04-06
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate...
    Medical condition: Moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Prematurely Ended) NO (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003504-12 Sponsor Protocol Number: GK_nilani_2012 Start Date*: 2012-10-05
    Sponsor Name:Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital
    Full Title: Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms.
    Medical condition: The catabolic effects induced by long-term glucocorticoid treatment.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005371-34 Sponsor Protocol Number: 2 39 00240 133 Start Date*: 2008-03-18
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study.
    Medical condition: Out patient suffering from friedreich ataxia aged from 12 to 20 years
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004558-24 Sponsor Protocol Number: CC-115-ST-001 Start Date*: 2012-06-29
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINIS...
    Medical condition: Subjects with advanced solid tumors, non-hodgkin lymphoma (NHL) and multiple myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002753-11 Sponsor Protocol Number: TofaSTAT17 Start Date*: 2018-01-25
    Sponsor Name:Tampere University Hospital
    Full Title: The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA)
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-003408-19 Sponsor Protocol Number: WX/80-003 Start Date*: 2012-01-25
    Sponsor Name:WILEX AG
    Full Title: A Phase I/II, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the MEK inhibitor WX-554 in patients with solid tumours
    Medical condition: Patients with advanced, metastatic and/or progressive solid tumours for whom there is no effective standard therapy available.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006881-40 Sponsor Protocol Number: AURA-6202-005 Start Date*: 2007-01-31
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy
    Medical condition: Treatment of Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003530-13 Sponsor Protocol Number: 18072011 Start Date*: 2011-12-20
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002399-28 Sponsor Protocol Number: RAP-ALS Start Date*: 2017-07-14
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis
    Medical condition: definite or probable ALS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000061-14 Sponsor Protocol Number: BCN04-DASA Start Date*: 2023-05-26
    Sponsor Name:Institut de Recerca Germans Trias i Pujol
    Full Title: Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People with HIV under Antiretroviral Treatment
    Medical condition: Human immunodeficiency virus (HIV)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000192-37 Sponsor Protocol Number: 2019_0007 Start Date*: 2021-10-04
    Sponsor Name:Hôpital Foch
    Full Title: Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide
    Medical condition: Patients with a diagnosis of Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003836-22 Sponsor Protocol Number: FLG-V001 Start Date*: 2019-12-11
    Sponsor Name:HUS Helsinki University Hospital
    Full Title: TWO-STAGE, TWO-ARM, OPEN-LABEL PHASE II STUDY OF VENETOCLAX IN COMBINATION WITH AZACYTIDINE IN ACUTE MYELOID LEUKEMIA PATIENTS SELECTED USING EX VIVO DRUG SENSITIVITY SCREENING
    Medical condition: Acute myeloid leukemia in patients who are non-fit for standard induction therapy (except acute promyelocytic leukemia) and present with de novo, secondary, released or refractory AML
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003124-16 Sponsor Protocol Number: KH176-204 Start Date*: 2021-01-12
    Sponsor Name:Khondrion B.V.
    Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease.
    Medical condition: Genetically confirmed mitochondrial disease
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:22:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA